Rallybio Corporation (RLYB) Revenue History
Annual and quarterly revenue from 2019 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RLYB Revenue Growth
Revenue Breakdown (FY 2024)
RLYB's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
RLYB Revenue Analysis (2019–2024)
As of May 8, 2026, Rallybio Corporation (RLYB) generated trailing twelve-month (TTM) revenue of $674,000, reflecting significant decline in growth of -29.1% year-over-year. The most recent quarter (Q3 2025) recorded $212,000 in revenue, up 0.0% sequentially.
Looking at the longer-term picture, RLYB's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $636,000 in 2024, representing a new all-time high.
Revenue diversification analysis shows RLYB's business is primarily driven by Collaboration And License Revenue (100%). With over half of revenue concentrated in Collaboration And License Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), and ARQT (+95.3% YoY), RLYB has underperformed the peer group in terms of revenue growth. Compare RLYB vs KYMR →
RLYB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RLYBCurrent | $674,000 | -29.1% | - | -9511.9% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARQT | $376M | +95.3% | - | -3.3% |
RLYB Historical Revenue Data (2019–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $636K | - | $636K | 100.0% | $-60,496,000 | -9511.9% |
| 2023 | $0 | - | $-150,000 | - | $-78,932,000 | - |
| 2022 | $0 | - | $-167,000 | - | $-67,884,000 | - |
| 2021 | $0 | - | $-109,000 | - | $-45,648,000 | - |
| 2020 | $0 | - | $-62,030 | - | $-25,303,000 | - |
| 2019 | $0 | - | $-26,344 | - | $-17,642,000 | - |
See RLYB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RLYB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RLYB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRLYB — Frequently Asked Questions
Quick answers to the most common questions about buying RLYB stock.
Is RLYB's revenue growth accelerating or slowing?
RLYB revenue declined -29.1% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $674000.00. This reverses the prior growth trend.
What is RLYB's long-term revenue growth rate?
Rallybio Corporation's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -29.1% is below this long-term average.
How is RLYB's revenue distributed by segment?
RLYB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2024 are available for download. Segment mix reveals concentration and diversification trends.